PartⅡ Individual Analysis of Brain Tumor ( )

6 PartⅡ Individual Analysis of Brain Tumor (98-000). Location of Tumor ) Location of Tumor Origin (98-000) oligodendoro- ependy- glioblas- medulloglioma* moma* toma astrocytoma* blastoma frontal lobe,688 (5.) 7 (57.6) 68 (9.7),00 (5.) 6 (0.9) temporal lobe,60 (6.5) 99 (.0) (.),99 (5.) (0.) parietal lobe 88 (.5) 75 (9.9) 5 (7.),05 (7.5) (0.6) occipital lobe 98 (.6) (.) (.) 9 (5.7) - (-) diffuse 88 (.) 5 (0.7) (0.) 7 (.) - (-) chiasmal region 6 (.5) (0.) (0.) 7 (0.) (0.) third ventricle, ant. 89 (.) (.7) 0 (.) (0.) (0.) third ventricle, post. 59 (0.8) (0.) 6 (0.9) 6 (0.) - (-) lat. vent. (ant. hornbody) 8 (.8) (5.7) 6 (9.0) 8 (0.5) (0.) lat. vent. (trigoum) 7 (0.5) (0.5) (.) (0.5) - (-) lat. vent. (temp. horn) 5 (0.) (0.) (0.6) 0 (0.) - (-) corpus callosim and septum pellucidum 60 (.) 7 (.) (0.) 76 (.0) (0.) rostral brain stem and basal ganglia 56 (6.9) (.7) (0.6) 77 (.7) - (-) pineal region 6 (0.6) (0.) 7 (.0) (0.) (0.) aqueduct (0.) - (-) (0.6) (0.0) - (-) cerebellar vermis 7 (.) - (-) 9 (5.6) (0.6) 8 (68.0) cerebellar hemisphere 79 (5.0) (0.) 5 (.6) 9 (.5) 6 (8.6) fourth ventricle (0.5) - (-) 58 (6.9) 6 (0.) 6 (7.8) cerebello- pontine 0 (0.) 6 (0.8) (.) 7 (0.) 6 (0.9) angle caudal brain stem(pons 5 (5.6) (0.) (.) 86 (.) 9 (.) and medulla) optic nerve 80 (.) - (-) - (-) (0.) - (-) calvarium 9 (0.) (0.) - (-) 6 (0.) (0.) skull-base, medial 8 (0.) (0.) - (-) 8 (0.) - (-) skull-base, paramedial (0.0) (0.) (0.) (0.0) - (-) others 9 (.) 6 (0.8) 6 (5.) 8 (.) 6 (0.9) 7,66 (00.0) 759 (00.0) 699 (00.0) 5,96 (00.0) 707 (00.0) * malignant cases included 5

7 ) Supra or Infratentorial astrocytoma * oligodendoro- ependy- glioblas medullomeningioma glioma moma toma blastoma supratentorial 6,90 (8.) 595 (98.) 09 (0.9) 5,7 (95.) 8 (.5),606 (79.) infratentorial,7 (5.) 8 (.) 85 (55.8) (.7) 670 (9.5),686 (5.6) supra & infra 6 (.6) (0.) 7 (.) 7 (.) (.0) 9 (5.) 7,687 (00.0) 605 (00.0) 5 (00.0) 6,05 (00.0) 709 (00.0) 7,06 (00.0) others 7 7 8 67 0 * malignant astrocytoma included ) Laterality astrocytoma * oligodendoro- ependy- glioblas- medullo glioma moma toma blastoma meningioma right,98 (8.6) 66 (.) 0 (9.7),68 (.0) (5.0) 6,878 (0.) left,96 (8.) 7 (9.) 00 (9.),505 (.) 6 (5.) 7,05 (.) bilateral 75 (9.8) 57 (9.5) 6 (8.9) 6 (0.5) 76 (.),666 (9.8) central,09 (.) (7.) 70 (5.) 0 (.5) 58 (78.7),77 (8.7) 7,6 (00.0) 60 (00.0) 58 (00.0) 5,956 (00.0) 68 (00.0) 7,07 (00.0) others 9 6 6 55 6 5 0 8 * malignant astrocytoma included Part II. Frequency of Tumors in Special Sites ) Frontal Lobe ) Parietal Lobe glioblastoma,00 (.) glioblastoma,05 (.) astrocytoma,5 (.6) astrocytoma 57 (8.) anapl. astrocytoma,6 (7.6) anapl. astrocytoma (6.8) * 7 (6.7) * 75 (.0) ependymoma * 68 (.0) ependymoma * 5 (.0) mixed glioma 0 (.) hemangiopericytoma 6 (0.) germinoma 6 (0.) malig. lymphoma 0 (8.) malig. lymphoma 9 (7.6) other sarcoma (0.) others sarcoma 8 (0.) others 5 (0.) others 9 (7.6),57 (00.0) 6,57 (00.0) 86 5 ) Temporal Lobe ) Occipital Lobe glioblastoma,99 (.) glioblastoma 9 (.6) astrocytoma 699 (9.6) astrocytoma 0 (.7) anapl. astrocytoma 56 (5.7) anapl. astrocytoma 97 (.) ependymoma * (0.6) ependymoma * (.9) 99 (.8) * (.0) ganglioglioma 69 (.9) neurinoma (0.) neurinoma 0 (0.6) malig. lymphoma 96 (.) mixed glioma (.) other sarcoma 5 (0.6) epidemoid (0.9) others 0 (.8) malig. lymphoma 0 (5.6) 796 (00.0) other sarcoma 9 (0.) others 07 (8.6),56 (00.0) Since meningioma is classified in special site 09 (e.g. convexity or parasagittal ), number of patients * malignant cases included with meningioma is excluded here.

8 5) Lateral Ventricle 6) Pituitary Grand-Chiasmal Region ependimoma * 6 (0.8) pituitary adenoma * 8,8 (76.) * (7.) craniopharyngioma,7 (5.7) plexus papiloma * 0 (.) germinoma 05 (.8) astrocytoma 0 (7.) astrocytoma 0 (.0) anapl. astrocytoma 7 (6.) anapl. astrocytoma (0.) glioblastoma 8 (.8) teratoma * 0 (0.) mixed glioma 5 (0.9) epidermoid 9 (0.) epidermoid (0.7) chordoma * (0.) neurinoma * (schwannoma) (.) dermoid 6 (0.) malig. lymphoma (5.5) others 5 (.) other sarcoma (0.5) 0,978 (00.0) others 7 (0.5) 585 (00.0) 6 8) Rostal Brain Stem, Basal Ganglia 7) Third Ventricle and Aqueduct astrocytoma (.8) astrocytoma (.) glioblastoma 9 (.6) glioblastoma 78 (9.8) germinoma 86 (0.6) germinoma 99 (7.) ependymoma * 6 (.0) ependymoma * 8 (0.6) anapl. astrocytoma 6 (.) anapl. astrocytoma 5 (6.7) craniopharyngioma 69 (.) craniopharyngioma 5 (0.) teratoma * (.6) teratoma * (0.) 5 (.9) * (0.9) pineoblastoma (0.) pituitary adenoma * (0.8) pituitary adenoma * 8 (5.9) malig. lymphoma 8 (7.0) malig. lymphoma 9 (.6) others 00 (.) others 8 (8.),0 (00.0) 8 (00.0) 0 * malignant cases included

9 9) Caudal Brain Stem 0) Cerebellum and Fourth Ventricle neurinoma * 9 (0.9) 9 (0.9) astrocytoma 8 (7.7) hemangioblastoma 70 (6.8) ependymoma * (.) anapl. astrocytoma (.8) epidermoid (.) glioblastoma 86 (8.) von reckinghausen 9 (0.9) polar spongioblas (0.) glioma(not verified) 0 (.5) neuroblastoma (0.) chordoma * (.) others (.8),05 (00.0) 5 668 (0.0) astrocytoma 55 (5.7) hemangioblastoma 9 (8.) ependymoma * (9.6) anapl. astrocytoma (.) glioblastoma (.0) epidermoid 85 (.5) plexus papilloma * 86 (.6) malig. lymphoma (.) neurinoma * 9 (0.9) neuroblastoma 7 (0.5) medulloepithelioma 8 (0.) others 9 (7.),6 (00.0) 7 Part II ) Cerebello-Pontine Angle ) Pineal Region neurinoma * 6,05 (88.6) epidermoid (6.0) von reckinghausen 97 (.) astrocytoma 8 (0.) anapl. astrocytoma (0.) glioblastoma 7 (0.) others (.) 6,8 (00.0) 9 * malignant cases icluded male female germinoma pineocytoma pineoblastoma teratoma malig. teratoma craniopharyngioma dermoid epidermoid others glioma(not verified) 5 5 57 58 56 50 98 585 0 65 6 6 5 5 5 5 (6.6) (8.0) (5.) (.9) (.9) (0.) (0.) (.) (8.) (0.),08 8,56 (00.0) 89

0. Extension of Tumors one side,570 (56.9),697 (56.) 70 (6.7) 90 (56.6) 00 (9.6) 0 (5.0),87 (56.9) (6.) ventricular system 55 (.) 9 (.9) 88 (.7) 8 (.) 85 (6.) 5 (.8) 90 (5.6) 5 (5.9) central 595 (.) (.0) 65 (0.8) 5 (5.7) 89 (7.5) (0.6) 77 (.0) 9 (7.) opposite side 90 (6.) 79 (9.) 56 (9.) 8 (.) (.) (6.9) 650 (0.9) (.0) supra + infratentorial 58 (.) 7 (.6) (0.) (0.6) 9 (.8) (0.6) 56 (0.9) 0 (.9) other 9 (9.9) 57 (5.) 0 (.) 7 (.) 6 (.7) (.) 57 (.6) 75 (5.5),55 5 (00.0)),0 (00.0)) 600 (00.0)) 59 (00.0)) 50 50 (00.0)) 60 (00.0)) 5,95 (00.0)) 686 (00.0)) 78 86 0 5 5. Brain Tumor Patients with Other Malignant Tumors primary p y tumor all primary tumor neurinoma von Recklinghausen's origin of disease second tumor no double tumor 65,0 (96.6) 6,606 (96.8) 9 (5.) other organ tumor,66 (.5) (.6) 7 (.) CNS 67 (0.9) 05 (.5) 7 (.8) 67, (00.0) 6,8 (00.0) 70 (00.0) 98 6 0 5. Macroscopic Features of Tumors (98-000) ) Character astrocytoma medullo- blastoma anapl. oligodendro- anapl. oligoastrocytoma glioma dendroglioma anapl. astrocytoma ependymoma glioblastoma ependymoma ependymoma glioblastoma meningioma solid,659 (59.7) 5 (58.) 5 (9.),78 (65.) (6.),59 (8.0) diffuse cystic (9.5) 5 (9.0) (6.5),009 (7.) 9 (.) 8 (0.5) circum- solid 88 (9.8) 5 (5.8) 67 (50.9) 669 (.6) 05 (.0) 5, (90.0) scribed cystic 88 (.0) (6.9) 7 (.5) 8 (5.7) 8 (5.5) 7 (.6),5 (00.0) 59 (00.0) 55 (00.0) 5,790 (00.0) 69 (00.0) 7,055 (00.0) 9 8 0 85 6 50

) Infiltration astrocytoma ependymoma glioblastoma meningioma none,668 (9.5) 8 (9.) 0 (85.9),5 (8.) 55 (7.6) 6,0 (.7) arachnoid 56 (6.5) 0 (7.6) 57 (.) 6 (.) 8 (.) 5 (.8) dura 5 (0.9) 6 (.) 9 (.9) 7 (.) 7 (.) 7, (8.) skull 5 (0.) (0.) - (-) (0.) - (-),0 (7.) scalp - (-) - (-) - (-) - (-) - (-) 0 (0.),96 (00.0) 59 (00.0) 68 (00.0) 5, (00.0) 60 (00.0) 5,8 (00.0) nos 89 9 87 59,56 0 9 8 557 50 80 nos : not otherwise specified Part II ) Extracranial Metastasis or Dissemination astrocytoma ependymoma glioblastoma meningioma none,69 (97.) 56 (98.) 76 (95.0) 5,50 (97.) 5 (79.) 6,60 (98.9) spinal cord 07 (.) (.9) (.6) (.) 6 (9.) 9 (0.9) other 6 (0.) - (-) (0.) 9 (0.) 0 (.5) 9 (0.),8 (00.0) 575 (00.0) 50 (00.0) 5,65 (00.0) 650 (00.0) 6,78 (00.0) 5 69 79 ) Diameter of Tumors < 0.5 cm 5 6 7 >8 astrocytoma ependymoma glioblastoma meningioma 8 (.0) 0 (.9) (.5) 88 (.6) 9 (.) 00 (.) 55 (6.) (.) 5 (5.) 8 (0.9) 8 (.) 67 (.) 85 (.) 7 (.7) 9 (9.0) 59 (6.6) 67 (0.5),9 (9.7),86 (9.) 8 (.) (9.),69 (.5) (7.7),67 (8.) 800 (9.8) 0 (.) (.),596 (9.) 0 (.8),7 (0.8) 78 (.8) 87 (6.) 8 (9.9),86 (.8) 8 (.0),7 (.) 8 (.5) (7.9) 7 (5.6) 56 (0.) 5 (.),06 (6.5) 56 (.) (.) 8 (.7) 6 (.7) (0.) 6 (.) 6 (.6) 9 (5.5) 7 (.5) 7 (5.0) 5 (0.8) 8 (.8),07 (00.0) 5 (00.0) 8 (00.0) 5,8 (00.0) 60 (00.0) 6,6 (00.0) 656 78 6 67 79,9

6. Performance State (Evaluation of Before and After Treatment) ) Before Treatment (98-000) astrocytoma ependymoma glioblastoma astrocytoma oligodendrogliomblastoma adenoma medullo- pituitary ependymoma glioblastoma meningioma pontine glioma,8 (6.) 6 (5.5) (6.) 790 (.) 0 (.0),007 (6.) 9 (.0) 9,67 (79.5),09 (.6) 7 (.) (.),08 (7.) 78 (5.5),09 (8.) 5 (.0),590 (.5) 56 (0.0) 56 (9.5) 50 (9.5) 878 (.9) 78 (.), (6.6) 9 (.) 5 (.7) 9 (0.8) 5 (8.6) 68 (.9),6 (.) (6.),09 (6.0) 7 (.0) (.) 5 8 (.) 0 (.7) 7 (.) 59 (0.) 0 (5.7) 96 (.) 55 (7.7) 5 (0.) 6 6 (.0) (.0) (.5) 600 (0.) 8 (.6) 6 (.5) 65 (9.) 66 (0.6) 7 56 (.) 8 (.) (.5) 599 (0.) 8 (5.5) 7 (.) 7 (0.0) 89 (0.8) blank 9 (0.6) (0.) - (-) 56 (0.9) (0.) 55 (0.9) 6 (.) 6 (0.5),56 (00.0) 59 (00.0) 59 (00.0) 5,899 (00.0) 697 (00.0) 7,099 (00.0) 78 (00.0),777 (00.0) 0 9 6 76 76 79 meningioma pontine glioma pituitary adenoma,757 (8.) 77 (6.5) 5 (8.9) 76 (.8) 5 (7.8) 9,7 (5.0) 69 (9.6) 8,08 (67.6),8 (8.) 70 (8.5) (7.0),75 (.5) 7 (.8),66 (6.8) 68 (.),889 (.) 7 (0.) 7 (7.9) 66 (.5) 85 (.) 8 (.8),6 (7.9) 6 (7.5) 9 (.) 65 (.) 59 (9.9) 8 (5.),86 (.) 8 (9.7),5 (8.8) 09 (9.) (.6) 5 99 (.) 0 (.) (8.) 60 (0.5) 0 (.7) (.0) 67 (9.) 7 (0.6) 6 77 (.9) 0 (.) (6.) 79 (8.) 6 (9.) 7 (.) 69 (9.6) 76 (0.6) 7 8 (0.6) (0.5) 0 (.9) 8 (.) 5 (.) (0.) 0 (.) 5 (0.0),570 (00.0) 596 (00.0) 50 (00.0) 5,9 (00.0) 70 (00.0) 7,7 (00.0) 78 (00.0),86 (00.0) 5 7 8 95 ) After Treatment (98-000). Normal; No complaints ; No evidence of disease. Normal activity with efforts; Some symptoms. Cares for self; Unable to carry on normal activity. Requires occational assistance; Cares for most needs 5. Disabled; Requires special care and assistance 6. Severely disabled; Hospitalized, death not imminent 7. Moribund; Fetal processes are rapidly progressing 9. Unknown

7. Pituitary Adenoma (98-000) ) Age Distribution male female 0 - (0.) (0.0) (0.0) 5-9 6 (0.) 7 (0.) (0.) 0 - (0.9) 8 (0.7) 9 (0.8) 5-9 8 (.5) 80 (.) 08 (.) 0-99 (.9) 68 (9.) 87 (6.9) 5-9 66 (5.) 695 (0.) 96 (8.0) 0 - (6.7) 5 (7.6) 867 (7.) 5-9 9 (8.6) 50 (7.7) 969 (8.) 0-507 (9.9) 59 (8.6),098 (9.) 5-9 56 (.0) 700 (0.),6 (0.6) 50-5 6 (.0) 675 (9.8),89 (0.8) 55-59 59 (.6) 65 (9.5), (0.) 60-6 58 (0.8) 580 (8.5),8 (9.) 65-69 0 (8.6) 90 (7.) 90 (7.8) 70-7 65 (5.) 0 (.) 568 (.8) 75-79 07 (.) (.8) (.9) 80-8 7 (0.5) 5 (0.) 5 (0.) 85-89 5 (0.) (0.0) 7 (0.) 90-9 - (-) (0.0) (0.0) 95 - - (-) - (-) - (-) 5,096 (00.0) 6,855 (00.0),95 (00.0) 6 05 Part II ) Radiotherapy (98-000) mode male female none, (87.5) 6,05 (90.8) 0,69 (89.) Co 60 96 (.9) 7 (.5) 70 (.) Linac (8.) (6.) 86 (7.) β-tron - (-) (0.0) (0.0) Heavy particle - (-) - (-) - (-) Isotope - (-) - (-) - (-) others (0.) 8 (0.) (0.) 5,065 (00.0) 6,8 (00.0),897 (00.0) 7 87 59

8. Pontine Glioma * (98-000) Age Distribution male female 0-9 (.8) 7 (.7) 96 (.) 5-9 9 (.5) (.) 08 (8.6) 0 - (8.6) 0 (.6) 7 (0.0) 5-9 7 (7.0) 6 (7.6) 5 (7.) 0 - (5.7) 8 (.) 0 (.) 5-9 6 (6.8) (6.) 7 (6.5) 0-8 (.7) (.) (.) 5-9 (6.0) (.) (.7) 0 - (.) (.) (.) 5-9 6 (.) 9 (.6) 5 (.) 50-5 8 (.7) 0 (.9) 8 (.8) 55-59 8 (.7) (.5) 0 (.) 60-6 (.) 8 (.) 0 (.7) 65-69 9 (.) 7 (.0) 6 (.) 70-7 (0.5) 6 (.7) 8 (.) 75-79 (.0) - (-) (0.5) 80-8 - (-) - (-) - (-) 85-89 (0.) - (-) (0.) 90-9 - (-) - (-) - (-) 95 - - (-) - (-) - (-) 8 (00.0) (00.0) 78 (00.0) * Pathologocally cases included